Nuveen
CRVS icon

Nuveen’s Corvus Pharmaceuticals CRVS Stock Holding History

Nuveen’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.42M Buy
161,821
+12,695
+9% +$176K ﹤0.01% 2477
2026
Q1 		$2.18M Buy
149,126
+81,062
+119% +$1.29M ﹤0.01% 2245
2025
Q4 		$524K Hold
68,064
– – ﹤0.01% 2852
2025
Q3 		$502K Hold
68,064
– – ﹤0.01% 2891
2025
Q2 		$272K Buy
+68,064
New +$248K ﹤0.01% 3085

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nuveen's CRVS Position: Q2 2026 in Review

Nuveen increased its Corvus Pharmaceuticals (CRVS) stake by 8.5% in Q2 2026, buying an estimated $176K and bringing the position to 161,821 shares worth $2.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2477.

Nuveen first reported a position in CRVS in Q2 2025 and has held it in 5 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Nuveen held 161,821 shares of Corvus Pharmaceuticals worth $2.42M as of Q2 2026.
  • Nuveen bought 12,695 Corvus Pharmaceuticals shares in Q2 2026, an estimated $176K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2477 holding.
  • Nuveen first reported a position in Corvus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.